title: [Clinical and economic repercussions of changing the erythropoietin administration route].
authors.forename: J R
authors.initials: JR
authors.lastname: Rodríguez
authors.forename: E
authors.initials: E
authors.lastname: Ruiz
authors.forename: G
authors.initials: G
authors.lastname: Vázquez
authors.forename: E
authors.initials: E
authors.lastname: Ruiz Cicero
mesh_terms: D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000191:economics; D000075202:Contraindications; D004305:Dose-Response Relationship, Drug; D016527:Drug Costs; D004921:Erythropoietin / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007501:Iron / Q000097:blood; D013030:Spain
chemical_list: D006454:Hemoglobins; D004921:Erythropoietin; D007501:Iron